Publications
242 results found
Raffel J, Dobson R, Gafson A, et al., 2014, Multiple sclerosis therapy and Epstein-Barr virus antibody titres, MULTIPLE SCLEROSIS AND RELATED DISORDERS, Vol: 3, Pages: 372-374, ISSN: 2211-0348
- Author Web Link
- Cite
- Citations: 14
Newbould RD, Nicholas R, Thomas CL, et al., 2014, Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis, NeuroImage: Clinical, Vol: 4, Pages: 641-648, ISSN: 2213-1582
BackgroundMultiple sclerosis (MS) is a heterogeneous disorder with a progressive course that is difficult to predict on a case-by-case basis. Natural history studies of MS have demonstrated that age influences clinical progression independent of disease duration.ObjectiveTo determine whether age would be associated with greater CNS injury as detected by magnetization transfer MRI.Materials and methodsForty MS patients were recruited from out-patient clinics into two groups stratified by age but with similar clinical disease duration as well as thirteen controls age-matched to the older MS group. Images were segmented by automated programs and blinded readers into normal appearing white matter (NAWM), normal appearing gray matter (NAGM), and white matter lesions (WMLs) and gray matter lesions (GMLs) in the MS groups. WML and GML were delineated on T2-weighted 3D fluid-attenuated inversion recovery (FLAIR) and T1 weighted MRI volumes. Mean magnetization transfer ratio (MTR), region volume, as well as MTR histogram skew and kurtosis were calculated for each region.ResultsAll MTR measures in NAGM and MTR histogram metrics in NAWM differed between MS subjects and controls, as expected and previously reported by several studies, but not between MS groups. However, MTR measures in the WML did significantly differ between the MS groups, in spite of no significant differences in lesion counts and volumes.ConclusionsDespite matching for clinical disease duration and recording no significant WML volume difference, we demonstrated strong MTR differences in WMLs between younger and older MS patients. These data suggest that aging-related processes modify the tissue response to inflammatory injury and its clinical outcome correlates in MS.
Muraro PA, Robins H, Malhotra S, et al., 2014, T cell repertoire following autologous stem cell transplantation for multiple sclerosis, Journal of Clinical Investigation, Vol: 124, Pages: 1168-1172, ISSN: 0021-9738
Autologous hematopoietic stem cell transplantation (HSCT) is commonly employed for hematologic and non-hematologic malignancies. In clinical trials, HSCT has been evaluated for severe autoimmunity as a method to “reset” the immune system and produce a new, non-autoimmune repertoire. While the feasibility of eliminating the vast majority of mature T cells is well established, accurate and quantitative determination of the relationship of regenerated T cells to the baseline repertoire has been difficult to assess. Here, in a phase II study of HSCT for poor-prognosis multiple sclerosis, we used high-throughput deep TCRβ chain sequencing to assess millions of individual TCRs per patient sample. We found that HSCT has distinctive effects on CD4+ and CD8+ T cell repertoires. In CD4+ T cells, dominant TCR clones present before treatment were undetectable following reconstitution, and patients largely developed a new repertoire. In contrast, dominant CD8+ clones were not effectively removed, and the reconstituted CD8+ T cell repertoire was created by clonal expansion of cells present before treatment. Importantly, patients who failed to respond to treatment had less diversity in their T cell repertoire early during the reconstitution process. These results demonstrate that TCR characterization during immunomodulatory treatment is both feasible and informative, and may enable monitoring of pathogenic or protective T cell clones following HSCT and cellular therapies.
Scalfari A, Neuhaus A, Daumer M, et al., 2014, Onset of secondary progressive phase and long-term evolution of multiple sclerosis, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 85, Pages: 67-75, ISSN: 0022-3050
- Author Web Link
- Cite
- Citations: 183
Abrahamsson S, Mattoscio M, Muraro PA, 2013, Haematopoietic stem cells for the treatment of MS, Multiple Sclerosis Immunology: A Foundation for Current and Future Treatments, Pages: 401-431, ISBN: 9781461479529
The last decade of research has achieved incredible advances in our understanding of stem cell biology. Amongst the best characterised types of stem cells are haematopoietic stem cells (HSC). Starting from the morphological description of bone marrow (BM)-resident cells in the early 1900s, studies on the physiological function of haematopoietic precursor cells have caught momentum in the 1960s and 1970s and have expanded exponentially following the increased availability of reagents and molecular methodologies in the 1980s and 1990s. In parallel, the clinical application of BM-and peripherally mobilised HSC-transplantation for haematological indications has been studied intensively in trials and applied in clinical practice. Since the mid-1990s, treatment of autoimmune disorders, including multiple sclerosis (MS), with autologous haematopoietic transplantation has been explored in clinical trials. More recently, an integrin-blocking antibody approved for treatment of MS has been shown to exert an effect on HSC recirculation as well as the expected effects on leucocyte trafficking.
Scalfari A, Neuhaus A, Daumer M, et al., 2013, The relationship between age, relapses and onset of progression in multiple sclerosis, 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Publisher: SAGE PUBLICATIONS LTD, Pages: 96-96, ISSN: 1352-4585
Scalfari A, Neuhaus A, Daumer M, et al., 2013, Frequent early relapses don't always predict severe disability in multiple sclerosis, 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Publisher: SAGE PUBLICATIONS LTD, Pages: 336-336, ISSN: 1352-4585
Hasni SA, Illei GG, Nikolov NP, et al., 2013, Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients, 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, Publisher: WILEY-BLACKWELL, Pages: S683-S684, ISSN: 0004-3591
- Author Web Link
- Cite
- Citations: 1
Colasanti A, Guo Q, Mulhert N, et al., 2013, [18F]PBR111 binding in lesional and peri-lesional multiple sclerosis white matter, 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Publisher: SAGE PUBLICATIONS LTD, Pages: 68-69, ISSN: 1352-4585
Nash RA, Hutton GJ, Racke MK, et al., 2013, 2-YEAR FOLLOW-UP RESULTS OF THE HALT MS CLINICAL TRIAL (ITN033AI), 18th Annual Meeting of Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Publisher: SAGE PUBLICATIONS LTD, Pages: 1407-1408, ISSN: 1352-4585
Bar-Or A, Muraro PA, 2013, Premature immune senescence in children with MS Too young to go steady, NEUROLOGY, Vol: 81, Pages: 778-779, ISSN: 0028-3878
- Author Web Link
- Cite
- Citations: 2
Abrahamsson SV, Angelini DF, Dubinsky AN, et al., 2013, Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis., Brain
Galea I, Lederer C, Neuhaus A, et al., 2013, A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis, EUROPEAN JOURNAL OF NEUROLOGY, Vol: 20, Pages: 1107-1109, ISSN: 1351-5101
- Author Web Link
- Cite
- Citations: 19
Ali R, Nicholas RSJ, Muraro PA, 2013, Drugs in Development for Relapsing Multiple Sclerosis, DRUGS, Vol: 73, Pages: 625-650, ISSN: 0012-6667
- Author Web Link
- Cite
- Citations: 47
Muraro P, Pasquini M, Atkins H, et al., 2013, Long-term outcomes after autologous haematopoietic cell transplantation for multiple sclerosis: a joint study from the Center for International Blood and Marrow Research (CIBMTR) and the European Group for Blood and Marrow Transplantat, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S1-S1, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 3
Scalfari A, Neuhaus A, Daumer M, et al., 2013, Onset of Secondary Progressive Phase and Disability Accumulation in Multiple Sclerosis, 65th Annual Meeting of the American-Academy-of-Neurology (AAN), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0028-3878
- Author Web Link
- Cite
- Citations: 1
Mattoscio M, Nicholas R, Malik O, et al., 2013, Circulating Hematopoietic Stem Cell Numbers during Natalizumab Treatment in Patients with Multiple Sclerosis: Association with Clinical and MRI Variables, 65th Annual Meeting of the American-Academy-of-Neurology (AAN), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0028-3878
Nash R, Hutton GJ, Racke M, et al., 2013, Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI), BMT Tandem Meetings, Publisher: ELSEVIER SCIENCE INC, Pages: S129-S129, ISSN: 1083-8791
- Author Web Link
- Cite
- Citations: 1
Scalfari A, Neuhaus A, Daumer M, et al., 2013, Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis, JAMA NEUROLOGY, Vol: 70, Pages: 214-222, ISSN: 2168-6149
- Author Web Link
- Cite
- Citations: 69
Sadnicka A, Sheerin U-M, Kaplan C, et al., 2013, Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease, MULTIPLE SCLEROSIS JOURNAL, Vol: 19, Pages: 123-125, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 7
Nash RA, Hutton GJ, Racke MK, et al., 2012, Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI), 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Choi SR, Howell OW, Carassiti D, et al., 2012, Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis, BRAIN, Vol: 135, Pages: 2925-2937, ISSN: 0006-8950
- Author Web Link
- Cite
- Citations: 253
Pasquini MC, Voltarelli J, Atkins HL, et al., 2012, Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol: 18, Pages: 1471-1478, ISSN: 1083-8791
- Author Web Link
- Cite
- Citations: 51
Reynolds R, Howell O, Choi S, et al., 2012, Meningeal inflammation and cortical pathology play a prominent role in primary progressive multiple sclerosis, 28th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: 119-120, ISSN: 1352-4585
Scalfari A, Neuhaus A, Daumer M, et al., 2012, The relationship between age and long-term evolution in multiple sclerosis, 16th Congress of the European-Federation-of-Neurological-Societies (EFNS), Publisher: WILEY-BLACKWELL, Pages: 345-345, ISSN: 1351-5101
- Author Web Link
- Cite
- Citations: 1
Scalfari A, Neuhaus A, Daumer M, et al., 2012, Relapses and late outcomes in multiple sclerosis, 16th Congress of the European-Federation-of-Neurological-Societies (EFNS), Publisher: WILEY-BLACKWELL, Pages: 28-28, ISSN: 1351-5101
Mattoscio M, Nicholas R, Malik O, et al., 2012, Differential Increase of Circulating Haematopoietic Stem Cells (HSC) Following Therapeutic alpha 4-Integrin Blockade in Multiple Sclerosis: Correlation between HSC Mobilization Status and Response to Treatment, 64th Annual Meeting of the American-Academy-of-Neurology (AAN), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0028-3878
Mattoscio M, Nicholas R, Malik O, et al., 2012, Differential Increase of Circulating Haematopoietic Stem Cells (HSC) Following Therapeutic alpha 4-Integrin Blockade in Multiple Sclerosis: Correlation between HSC Mobilization Status and Response to Treatment, 64th Annual Meeting of the American-Academy-of-Neurology (AAN), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0028-3878
Scalfari A, Neuhaus A, Daumer M, et al., 2012, Long Term Evolution of "Benign" Multiple Sclerosis Patients in the London Ontario Database, 64th Annual Meeting of the American-Academy-of-Neurology (AAN), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0028-3878
Saccardi R, Freedman M, Sormani MP, et al., 2012, A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper, Multiple Sclerosis
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.